Qualigen Therapeutics Faces Delisting Notice
Ticker: AIXC · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1460702
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Qualigen got a notice about possibly getting delisted. Big trouble.
AI Summary
Qualigen Therapeutics, Inc. filed an 8-K on September 8, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principal executive offices are located at 5857 Owens Avenue, Suite 300, Carlsbad, California. The filing date indicates the earliest event reported was September 4, 2025.
Why It Matters
This filing signals potential issues with Qualigen Therapeutics' continued listing on an exchange, which could impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards indicates significant financial or operational distress, posing a substantial risk to the company and its investors.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- September 4, 2025 (date) — Earliest event reported
- September 8, 2025 (date) — Filing date
- 5857 Owens Avenue, Suite 300, Carlsbad, California (location) — Principal executive offices
- 001-37428 (other) — Commission File Number
FAQ
What specific listing rule or standard has Qualigen Therapeutics, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Qualigen Therapeutics, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 4, 2025.
What is the Commission File Number for Qualigen Therapeutics, Inc.?
The Commission File Number for Qualigen Therapeutics, Inc. is 001-37428.
Where are Qualigen Therapeutics, Inc.'s principal executive offices located?
Qualigen Therapeutics, Inc.'s principal executive offices are located at 5857 Owens Avenue, Suite 300, Carlsbad, California.
What is the standard industrial classification for Qualigen Therapeutics, Inc.?
The standard industrial classification for Qualigen Therapeutics, Inc. is Pharmaceutical Preparations [2834].
Filing Stats: 749 words · 3 min read · ~2 pages · Grade level 13 · Accepted 2025-09-08 16:30:39
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share QLGN The Nasdaq Stock Mar
- $2.5 m — intain stockholders' equity of at least $2.5 million, by July 28, 2025. The Company's
- $1.6 m — lders' equity of approximately negative $1.6 million, and accordingly the Company did
- $4.3 million — enerating net proceeds of approximately $4.3 million. The Company believes this financing ma
- $600,000 — any's stockholders' equity of more than $600,000. The Panel noted that although the Co
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001641172-25-026864.txt ( ) — 198KB
- qlgn-20250904.xsd (EX-101.SCH) — 3KB
- qlgn-20250904_lab.xml (EX-101.LAB) — 33KB
- qlgn-20250904_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: September 8, 2025 By: /s/ Kevin Richardson II Name: Kevin Richardson II Title: Interim Chief Executive Officer